Multi-targeted approach in the treatment of thyroid cancer

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 935-947

  Pinchot, Scott N ^a   Sippel, Rebecca S ^a   Chen, Herbert ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Glycogen synthase kinase 3 (GSK 3 ); RET tyrosine kinase (RTK); Thyroid carcinoma; Vascular endothelial growth factor receptor (VEGFR)

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; IODINE 131; LEVOTHYROXINE; NOTCH1 RECEPTOR; PROTEIN P53; SUNITINIB; THYROTROPIN; TYROSINE KINASE RECEPTOR; VANDETANIB;

ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG ERUPTION; DRUG TARGETING; DYSPHAGIA; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; PAIN; PARATHYROID GLAND PAIN; POINT MUTATION; PROTO ONCOGENE; QT PROLONGATION; RADIOIODINATION; REVIEW; SIALOADENITIS; SUBTOTAL THYROIDECTOMY; SURVIVAL RATE; TASTE DISORDER; THYROID CANCER; THYROIDECTOMY; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

EID: 56749140670     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. American Cancer Society. 2007. Cancer Facts and Figures 2007. Accessed 8 January 2008. URL: http://www.cancer.org/downloads/STT/ CAFF2007PWSecured.pdf.
2. Attie JN, Khafif RA, Steckler RM. 1971. Elective neck dissection in papillary carcinoma of the thyroid. Surgery, 111:604-9.
3. Bauer D. 1997. Low thyrotropin levels are not associated with bone loss in older women:A prospective study. J Clin Endocrinol Metab, 82:2931-5.
4. Beressi N, Campos JM, Beressi JP, et al. 1998. Sporadic medullary microcarcinoma of the thyroid:a retrospective analysis of eighty cases. Thyroid, 8:1039-44.
5. Bilimoria KY, Bentrem DJ, Ko CY, et al. 2007. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg, 246:375-81.
6. Bocca E, Pignataro O, Sasaki CT. 1980. Functional neck dissection: a description of operative technique. Arch Otolaryngol, 106:524-7.
7. Bocca E, Pignataro O, Oldini C, et al. 1984. Functional neck dissection: an evaluation and review of 843 cases. Laryngoscope, 94:942-5.
8. Burmeister LA. 1994. Thyroid hormone in the treatment of thyroid cancer. Thyroid Today, 17:1-9.
9. British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer (2nd ed.). Accessed 9 January 2008. URL: http://www.british-thyroid-association.org/ Thyroid_cancer_guidelines_2007.pdf.
10. Byar DP, Green SB, Sor P, et al. 1979. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer, 15:1033-41.
11. Cady B, Sedhwick CE, Meissner WA, et al. 1979. Risk factor analysis in differentiated thyroid cancer. Cancer, 43:810-20.
12. Carlomagno F, Vitagliano D, Guida T, et al. 2002. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res, 62:7284-90.
13. Cheema Y, Repplinger D, Elson D, et al. 2006. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol, 13:1524-8.
14. Chen H, Kunnimalaiyaan M, Van Gompel JJ, et al. 2005. Medullary thyroid cancer:The functions of raf-1 and human achaete-scute homologue-1. Thyroid, 15:511-21.
15. Chen H, Nicol TL, Udelsman R. 1999. Clinically significant, isolated metastatic disease to the thyroid gland. World J Surg, 23:177-80.
16. Chen H, Nicol TL, Zeiger MA, et al. 1998b. Hurthle cell neoplasms of the thyroid:Are there factors predictive of malignancy? Ann Surg, 227:542-6.
17. Chen H, Roberts JR, Ball DW, et al. 1998c. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg, 227:887-95.
18. Chen H, Udelsman R. 1998. Papillary thyroid carcinoma: Justification for total thyroidectomy and management of lymph node metastases. Surg Oncol Clin N Am, 7:645-64.
19. Chong GC, Beahrs OH, Sizemore GW, et al. 1975. Medullary carcinoma of the thyroid gland. Cancer, 35:695-704.
20. Clark OH. 1981. TSH suppression of thyroid nodules and thyroid cancer. World J Surg, 5:39-46.
21. Clark OH. 1982. Total thyroidectomy:The treatment of choice for patients with differentiated thyroid cancer. Ann Surg, 196:361-70.
22. Clark OH. 1985a. Endocrine surgery of the thyroid and parathyroid glands. St. Louis, MO: The C.V. Mosby Company.
23. Clark OH, Gerend PL. 1985b. Thyrotropin receptor-adenylate cyclase system in Hurthle cell neoplasms. J Clin Endocrinol Metab, 61:773-8.
24. Cohen P, Frame S. 2001. The renaissance of GSK3. Nat Rev Mol Cell Bio, 2:769-76.
25. Colonna M, Grande E, Jónasson JG, et al. 2006. Variation in relative survival of thyroid cancers in Europe: Results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study). Eur J Cancer, 42:2598-608.
26. Cooper DS, Doherty GM, Haugen BR, et al. 2006. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16:109-42.
27. Dean DS, Hay ID. 2000. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control, 7:229-39.
28. DeGroot LJ, Kaplan EL, McCortick M, et al. 1990. Natural history, treatment, and course of papillary thyroid cancer. J Clin Endocrinol Metab, 71:414-24.
29. Duren M, Siperstein AE, Shen W, et al. 1999. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery, 126:13-9.
30. Emerick GT, Duh QY, Siperstein AE, et al. 1993. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer, 72:3287-95.
31. Frazell EL, Foote FW. 1955. Papillary thyroid carcinoma:pathologica] findsings in cases with and without clinical evidence of cervical node involvement. Cancer, 8:1164-70.
32. Fogelfeld L, Wiviott MB, Shove-Freedman E, et al. 1989. Recurrence of thyroid nodules after removal in patients irradiated in childhood for benign conditions. N Engl J Med, 320:835-40.
33. Gimm, O, Ukkat J, Dralle H. 1999. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg, 22:562-7.
34. Grebe SK, Hay ID. 1996. Thyroid cancer nodal metastases:biologic significance and therapeutic considerations. Surg Oncol Clin N Am, 5:43-63.
35. Greenblatt DY, Elson D, Mack E, et al. 2007. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg, 30:108-12.
36. Hanks JB. 2004. Thyroid Malignancies. In Townsend CM, Beauchamp RD, Evers BM, et al. (eds). Sabiston Textbook of Surgery. 17th ed. Philadelphia: Saunders. p. 965-73.
37. Hardt SE, Sadoshima J. 2002. Glycogen synthase kinase-3β:a novel regulator of cardiac hypertrophy and development. Circ Res, 90:1055-63.
38. Harwood AJ, Plyte SE, Woodgett J, et al. 1995. Glycogen synthase kinase 3 regulates cell fate in Dictyostelium Cell, 80:139-48.
39. Haugen BR. 1999. Management of the patient with progressive radio-iodine non-responsive disease. Semin Surg Oncol, 16:34-41.
40. Hay ID, Bergstralh EJ, Goellner JR, et al. 1993. Predicting outcome in papillary thyroid cancer: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery, 114:1050-8.
41. Hay ID, Grant CS, Bergstralh EJ, et al. 1998. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery, 124:958-66.
42. Hedinger C, Williams ED, Sobin LH, eds. 1988. Histologic typing of thyroid tumors. In: International Histological Classification of Tumors, No.11. Geneva: World Health Organization; 1-18.
43. Heijckmann AC, Huijberts MS, Guesens P, et al. 2005. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Fur J Endocrinol, 153:23-9.
44. Hoelting T, Siperstein AE, Clark OH, et al. 1994. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab, 79:401-8.
45. Holden SN, Eckhardt SG, Basser R, et al. 2005. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol, 16:1391-7.
46. Hundahl SA, Fleming ID, Fremgen AM, et al. 1998. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer, 83:2638-48.
47. Ito Y, Miyauchi A. 2007. Appropriate treatment for asymptomatic papillary microcarcinoma of the thyroid. Expert Opin Pharmacother, 8:3205-15.
48. Ito Y, Uruno T, Nakanao K, et al. 2003. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid, 13(4):381-7.
49. Kadesch T. 2004. Notch signaling: The demise of elegant simplicity. Curr Opin Genet Dev, 14:506-12.
50. Katoh R, Sasaki J, Kurihara H, et al. 1992. Multiple thyroid involvement (intraglandular metastases) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer, 70:1585-90.
51. Kebebew E, Clark OH. 2000. Medullary thyroid cancer. Curr Treat Options Oncol, 1:359-67.
52. Kebebew E, Weng J, Bauer J, et al. 2007. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 246:466-71.
53. Kendall-Taylor P, Guidelines Working Group. 2003. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf), 58:400-2.
54. Kim DW, Jo YS, Jung HS, et al. 2006. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab, 91:4070-6.
55. Kim S, Yazici TD, Calzada G, et al. 2007. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther, 6:1785-92.
56. Kimura ET, Nikiforova MN, Zhu Z, et al. 2003. High prevalence of BRAF mutations in thyroid cancer:genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63:1454-7.
57. 131 therapy in the management of thyroid cancer. A prospective study. Cancer, 40:195-202.
58. Küçük NO, Tari P, Tokmak E, et al. 2007. Treatment for microcarcinoma of the thyroid - clinical experience. Clin Nucl Med, 32:279-81.
59. Kunnimalaiyaan M, Chen H. 2006. The Raf-1 pathway:a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs, 17:139-42.
60. Kunnimalaiyaan M, Chen H. 2007. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist, 12:535-42.
61. Kunnimalaiyaan M, Haymart M, Chen H. 2007a. Tumor suppressor role of Notch1 and Raf-1 signaling in medullary thyroid cancer cells. Translational Oncogenomics, 2:43-7.
62. Kunnimalaiyaan M, Vaccaro AM, Ndiaye M, et al. 2006. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem, 281:39819-30.
63. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, et al. 2007b. Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther, 6:1151-8.
64. Lam KY, Lo CY, Chan KW, et al. 2000. Insular and anaplastic carcinoma of the thyroid:A 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg, 231:329-38.
65. Lang BH, Lo CY. 2007. Surgical options in undifferentiated thyroid carcinoma. World J Surg, 31:969-77.
66. Lundgren CI, Hall P, Dickman PW, et al. 2006. Clincally significant prognostic factors for differentiated thyroid carcinoma:a population-based, nested case-control study. Cancer, 106:524-31.
67. Machens A, Holzhausen HJ, Dralle H. 2004. Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg, 139:43-5.
68. Machens A, Hauptmann S, Dralle H. 2007. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg, 31:1960-5.
69. Maillard I, Pear WS. 2003. Notch and cancer:Best to avoid the ups and downs. Cancer Cell, 3:203-5.
70. Malaguarnera R, Vella V, Vigneri R, et al. 2007. p53 family proteins in thyroid cancer. Endocr Relat Cancer, 14:43-60.
71. Manie S, Santoro M, Fusco A, et al. 2001. The RET receptor:function in development and dysfunction in congenital malformation. Trends Genet, 17:580-9.
72. Mazzaferri E. 1988. Papillary thyroid carcinoma:factors influencing prognosis and current therapy. Semin Oncol, 14:315-32.
73. Mazzaferri EL. 1999. NCCN thyroid carcinoma practice guidelines. Oncology, 13:391-42.
74. Mazzaferri EL. 2007. Management of low-risk differentiated thyroid cancer. Endocr Pr, 13:498-512.
75. Mazzaferri EL, Jhiang SM. 1994. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 97:418-28.
76. Mazzaferri E, Young RL, Oertel JE, et al. 1977. Papillary thyroid carcinoma: The impact of therapy in 576 patients. Medicine, 56:171-96.
77. Mazzaferri E, Young RL. 1981. Papillary thyroid carcinoma:A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med, 70:551-558.
78. Mitsiades CS, Kotoula V, Poulaki V, et al. 2006. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma:mutational and functional analysis. J Clin Endocrinol Metab, 91:3662-6.
79. Moretti F, Farsetti A, Soddu S, et al. 1997. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene, 14:729-40.
80. [NCI] National Cancer Institute Surveillance Epidemiology and End Results Database, US National Institutes of Health. URL: http://seer.cancer.gov/statfacts/html/thyro.html; accessed March 28, 2008.
81. Olivier M, Eeles R, Hollstein M, et al. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat, 19:607-14.
82. Ozata M, Suzuki S, Miyamoto T, et al. 1994. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab, 79:98-105.
83. Paloyan E, Walker RP, Lawrence AM. 1998. Guidelines for the use of radioiodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer. Surg Oncol Clin N Am, 7:665-80.
84. Park JI, Strock CJ, Ball DW, et al. 2003. The ras/raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol, 23:543-54.
85. Perros P, Thyroid Cancer Guidelines Update Group. 2007. Introduction to the updated guidelines on the management of thyroid cancer. Clin Med, 7:321-2.
86. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab, 81:4318-23.
87. Qubain SW, Nakano S, Baba M, et al. 2002. Distribution of lymph node micrometastases in pN0 well-differentiated thyroid carcinoma. Surgery, 131:249-56.
88. Ravi RK, Thiagalingam A, Weber E, et al. 1999. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small cell lung cancer cells. Am J Respir Cell Mol Biol, 20:543-9.
89. Ravi RK, Weber E, McMahon, et al. 1998. Activated raf-1 causes growth arrest in human small cell lung cancers. J Clin Invest, 101:153-9.
90. Rougier P, Parmentier C, Laplanche A, et al. 1983. Medullary thyroid carcinoma:prognostic factors and treatment. INt J Radiat Oncol Biol Phys, 9:161-169.
91. Saad MF, Ordonez NG, Rashid RK, et al. 1984. Medullary carcinoma of the thyroid:a study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore), 63:319-342.
92. Saltman B, Singh B, Hedvat CV, et al. 2006. Patterns of expression of cell cycle/apoptosis genes along the spectmm of thyroid carcinoma progression. Surgery, 140:899-906.
93. Salvatore G, De Falco V, Salerno P, et al. 2006. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res, 12:1623-9.
94. Sanders LE, Cady B. 1998. Differentiated thyroid cancer:Reexamination of risk groups and outcome of treatment. Arch Surg, 133:419-25.
95. Sawka AM, Lakra DC, Lea J, et al. 2008a. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol, 68:610-7.
96. Sawka AM, Lakra DC, Lea J, et al. 2008b. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol, Feb 13.
97. Schneider AB, Favus MJ, Stachoura ME, et al. 1978. Incidence, prevalence, and characteristics of radiation-induced thyroid tumors. Am J Med, 64:243-52.
98. Scollo C, Baudin E, Travalgi JP, et al. 2003. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab, 88:2070-5.
99. Shaha AR. 1998. Management of the neck in thyroid cancer. Otolaryngol Clin North Am, 31:823-31.
100. Sherman SI. 2003. Thyroid carcinoma. Lancet, 361:501-11.
101. Shiba E, Miyauchi K, Kobayashi T, et al. 1989. The effect of thyroid hormone on the growth of thyroid cancer [Japanese]. Gan To Kagaku Ryoho, 16:3678-84.
102. Silverberg SG, Hutter RVP, Foote FW Jr. 1970. Fatal carcinoma of the thyroid: histology, metastases, and causes of death. Cancer, 25:792-802.
103. Simon D, Goretzki PE, Witte J, et al. 1996. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg, 20:860-6.
104. Sippel RS, Carpenter JE, Kunnimalaiyaan M, et al. 2003. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery, 134:866-71.
105. Solans R, Bosch JA, Galofré P, et al. 2001. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med, 42:738-43.
106. Sugino K, Ito K, Mimura T, et al. 2002. The important role of operations in the management of anaplastic carcinoma. Surgery, 131:245-8.
107. Sywak M, Cornford L, Roach P, et al. 2006. Routine ipsilateral level VI lymphadenopathy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery, 140:1000-7.
108. Tamura T, Minami H, Yamada Y, et al. 2006. A Phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol, 1:1002-9.
109. Task Force TC. 2001. AACE/AAES medical/surgical guidelines for clinical practice:Management of thyroid carcinoma. Endocr Pr, 7:203-20.
110. Taylor T, Specker B, Robbins J, et al. 1989. Outcome after treatment of high-risk papillary and non- Hürthle-cell follicular thyroid carcinoma. Ann Int Med, 129:622-7.
111. Tennvall J, Lundell G, Hallquist A, et al. 1994. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Cancer, 74:1348-54.
112. Thyroid Carcinoma Task Force. 2001. AACE/AAES medical/surgical guidelines for clinical practice:management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract, 7:202-20.
113. Trovisco V, Soares P, Sobrinho-Simoes M. 2006. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol, 37:781-6.
114. Udelsman R, Chen H. 1999. The current management of thyroid cancer. Adv Surg, 33:1-27.
115. Vaccaro A, Chen H, Kunnimalaiyaan M, et al. 2006. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs, 17:849-53.
116. Vidal M, Wells S, Ryan A. 2005. ZD6474 suppresses oncogenic RET isoforms in a Drosphila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res, 65:3538-41.
117. Wedge SR, Ogilvie DJ, Dukes M, et al. 2002. ZD6474 inhibits vascular endothelial growth factor signaling, angiongenesis, and tumor growth following oral administration. Cancer Res, 62:4645-55.
118. Wells S, Gosnell J, Gagel RF, et al. 2007. Vandetanib in metastatic hereditary medullary thyroid cancer:follow-up results of an open-label phase II trial [abstract]. Proc Am Soc Clin Oncol. Abst 6018.
119. White ML, Gauger PG, Doherty G. 2007. Central lymph node dissection in differentiated thyroid cancer. World J Surg, 31:895-904.
120. Wong JB, Kaplan MM, Meyer KB, et al. 1990. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma:a decision analytic perspective. Endocrinol Metab Clin North Am, 19:741-60.
121. Xing M. 2005. BRAF mutation in thyroid cancer. Endocr-Relat Cancer, 12:245-62.
122. Yeh MW, Rougier JP, Park JW, et al. 2006. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/ gelatinase A. Endocr-Relat Cancer, 13:1173-83.
123. Yoon K, Gaiano N. 2005. Notch signaling in the mammalian central nervous system:Insights from mouse mutants. Nat Neurosci, 8:709-15.
124. Young RL, Mazzaferri EL, Rahe AJ, et al. 1980. Pure follicular thyroid carcinoma:impact of therapy in 214 patients. J Nuclear Med, 21:733-7.
125. Yutan E, Clark OH. 2001. Hürthle cell carcinoma. Curr Treat Options Oncol, 2:331-5.